Human observational studies link platelet-to-lymphocyte ratio with sarcopenia, frailty and osteoporosis, while a study finds no clear link with primary sarcopenia. Hip-fracture studies report mortality associations or no clear link. An observational study reports no clear improvement in frailty classification when the ratio is added to a core geriatric model.
46 findings in 42 papers from 2017 to 2026, 10 of them since April 2026
“platelet-to-lymphocyte ratio (PLR) and platelet-to-leukocyte ratio (PWR) demonstrated modest inverse associations (5-13% decreased risk).”
Platelet-to-lymphocyte ratio is linked with worse physical function in humans (non-dialysis chronic kidney disease) (OR = 1.004, 95% CI: 1.001–1.006, P = 0.014).
“PLR (OR = 1.004, 95% CI: 1.001–1.006, P = 0.014) were independently associated with physical function dependence”
Platelet-to-lymphocyte ratio is associated with sarcopenia in humans (cross-sectional analysis; highest vs lowest PLR group after adjustment for covariates) (OR 1.455 [1.177,1.799]).
“neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) were significantly associated with sarcopenia”
Humanscross-sectional analysis; highest vs lowest PLR group after adjustment for covariatesn = 4,224
Platelet-to-lymphocyte ratio is associated with sarcopenia in humans (Highest serum PLR (≥155) versus lowest PLR (<90), adjusted for covariates) (OR 2.36, 95% CI 1.21–3.31; p < 0.01).
“participants with highest serum PLR values (≥155) had 2.36 times greater risk of sarcopenia than those with lowest PLR values”
HumansHighest serum PLR (≥155) versus lowest PLR (<90), adjusted for covariatesn = 3,671
Platelet-to-lymphocyte ratio is associated with osteoporosis in humans (exploratory age-stratified analysis; association not observed in older groups) (OR 1.09 per 10-unit increase; P = 0.013).
“PLR was associated with osteoporosis among women aged 50-64 years (OR 1.09 per 10-unit increase, P = 0.013), but not in older groups.”
Humansexploratory age-stratified analysis; association not observed in older groupsfemales
Platelet-to-lymphocyte ratio is linked with a higher risk of osteoporosis in humans (OR = 1.221, CI = 1.001-1.488, P = 0.048).
“Individuals in the highest tertiles of PLR had a 1.221-fold increase in osteoporosis prevalence compared to those in the lowest tertiles (OR = 1.221, CI = 1.001-1.488, P = 0.048).”
Platelet-to-lymphocyte ratio predicts frailty in maintenance hemodialysis patients (AUC 0.799).
“The area under the receiver operating characteristic (ROC) curve of NLR and PLR in diagnosing frailty in MHD patients was 0.859 and 0.799, respectively.”
Platelet-to-lymphocyte ratio is associated with coronary artery disease in humans (Free of coronary artery disease at baseline) (5–13% decreased risk across PLR and PWR).
“platelet-to-lymphocyte ratio (PLR) and platelet-to-leukocyte ratio (PWR) demonstrated modest inverse associations (5-13% decreased risk).”
HumansFree of coronary artery disease at baselinen = 475,134
Platelet-to-lymphocyte ratio is linked with a higher risk of mortality in humans (primary lung cancer, first chemotherapy course) (HR = 1.39, 95% CI = 1.17-1.64, P < 0.001).
“or a PLR ≥ 125.11 (HR = 1.39, 95% CI = 1.17-1.64, P < 0.001) compared to those with values below these thresholds.”
Humansprimary lung cancer, first chemotherapy coursen = 926
Platelet-to-lymphocyte ratio is associated with incident atrial fibrillation in humans (type 2 diabetes mellitus; covariate-adjusted Model 3) (HR 1.030, 95% CI 0.993–1.068; P=0.112).
“The PLR association was not statistically significant (1.030; 0.993–1.068; P=0.112).”
A human preprint links platelet-to-lymphocyte ratio to cardiovascular mortality, whereas another reports no mortality association at hemodialysis initiation. A cervical screening study reports prediction of high-grade cervical lesions in women. Separate human studies link it to hippocampal volume fraction longitudinally and lower chronic kidney disease risk in obesity.
Cardiovascular conditions affected 28.2% of cancer survivors with obesity, versus 15.6% of adults with obesity alone, despite lower levels of an inflammation marker.Cardiovascular conditions affected 28.2% of cancer survivors with obesity, versus 15.6% of adults with obesity alone, despite lower levels of an inflammation marker.